Case Reports
Immunohistochemical Analysis of CCR6 Expression in Four Psoriasis Patients
Yuta Kurashige* and Tetsuo Nagatani
Corresponding Author: Dr. Yuta Kurashige, Department of Dermatology, Tokai University School of Medicine, 143 Shimokasuya, Isehara-shi, Kanagawa 259-1193, Japan, Tel: +81.463.93.1121 ; Fax: +81.4632.93.9387 ; E-mail:
Received: January 23, 2017; Accepted: January 30, 2017; Published: February 25, 2017;
Citation: Kurashige Y & Nagatani T. (2017) Immunohistochemical Analysis of CCR6 Expression in Four Psoriasis Patients. Dermatol Clin Res, 3(1): 118-120.
Copyrights: ©2017 Kurashige Y & Nagatani T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keywords: Psoriasis, CCR6, Immunohistochemistry, Localization


Chemokines and chemokine receptors have been known to play a crucial role in directing the movement of mononuclear cells that is involved in the systemic immune system. In recent years, the acquired immunity involving Interleukin 23 (IL-23) / T helper 17 (Th17) axis has been considered to have an important role in pathophysiolosy of psoriasis [1]. Among the chemokines and chemokine receptors having an association with IL-23/ Th17 axis, chemokine (C-C motif) ligand (CCL) 20, and CC-chemokine receptor (CCR) 6, only known receptor for CCL20, has been focused attention according to the following findings of the studies. (1) Both CCR6 and CCL20 have reported to be expressed at significantly higher levels in lesional psoriatic skin than in non-lesional skin. (2) CCR6 is expressed on almost all IL-17A- and IL-22-producing CD4+ T cells those are expected as a key player in an IL-23/ Th17 axis. (3) Mice deficient in CCR6 fail to develop IL-23-induced psoriasis-like lesion. On the other hand, it has been reported that more than 75% of resident T cells in normal skin also express CCR6, accordingly, CCR6 may be involved in migration of T cells not only in inflammation state, but also in the steady state. According to the previous studies using clinical samples of psoriasis patients, up-regulation of CCR6 mRNA expression and immunohistochemical localization of CCR6 protein in the skin lesions has been reported. Nevertheless, the association between CCR6 expression and clinical characteristics has never been argued. In this paper, we performed immunohistochemical analysis of CCR6 in four psoriasis patients, and discuss about an association between CCR6 expression and clinical characteristics of the patients.

The four patients clinically diagnosed as plaque-type psoriasis vulgaris were recruited for the investigation (Table 1). Samples of lesional skin were taken using 4 mm punch biopsy. To confirm the diagnosis of psoriasis, histopathological examination was performed in all lesional skin samples. Psoriasis Area and Severity Index (PASI) was determined subjectively by dermatologists. Clinical characteristics of the patients were obtained from the medical records. Normal skin samples were obtained from three persons who underwent skin grafting. Informed consent was given to all participants. Formalin-fixed, paraffin-embedded tissue samples were cut at 3μm. The applied antibody was a rabbit polyclonal anti-CCR6 antibody (1:50, clone; LSBio, WA). Immunohistochemical stains were performed on an automated slide stainer for immunohistochemistry (Leica BOND-III, Leica Biosystems).

The immunohistochemical results were demonstrated in Figure 2. All psoriatic samples showed similar results, namely, robust expression of CCR6 in the inflammatory lymphocytes which had infiltrated into the papillary and perivascular superficial dermis (Figure 2a-2d). Although the normal skin contained a few dermal lymphocytes, CCR6 expression in those cells was less prominent than in the psoriatic samples (Figure 2e). On the other hand, in both psoriatic and normal skin, keratinocytes in the basal and suprabasal layer of the epidermis showed comparable CCR6 expression.

There have been a large number of studies investigating pathophysiological roles of IL-23/ Th17 axis. To our knowledge, only a few studies of immunohistochemical CCR6 expression in psoriasis patients has been published. Antiga et al. [2] reported that CCR6-positive and CD4-positive cells were both mainly located in the superficial dermis, an observation consistent with our own. Moreover, in our study, immunohistochemical results demonstrated that CCR6 was also expressed on basal and suprabasal layer of epidermis, which was consistent with the previous report by Charbonnier et al. [3]. They theorized that epidermis-expressed CCR6 had a role for a homing of Langerhans cells and a keratinocyte homeostasis. Although we could not elucidate precise characteristics of the CCR6-positive infiltrative lymphocytes, it may be possible that such lymphocytes in the lesional psoriatic skin play a role in promotion of inflammatory cell migration. Besides, recent studies noted that CCR6 is expressed on almost all Th17 cells (IL-17A- and IL-22-producing CD4+ T cells). Accordingly, we speculate that the CCR6-positive infiltrative lymphocytes shown in the lesional psoriatic skin contain some Th17 cells. 


This work was supported by Tokyo Medical University Research Grant.


None declared.

  1. Hedrick MN, Lonsdorf AS, Hwang ST, et al. (2010) CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets 14: 911-922.
  2. Antiga E, Volpi W, Chiarini C, et al. (2010) The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris. Int J Immunopathol Pharmacol 23: 767-774.
  3. Charbonnier AS, Kohrgruber N, Kriehuber E, et al. Macrophage inflammatory protein 3alpha is involved in the constitutive trafficking of epidermal langerhans cells. (1999) J Exp Med 190: 1755-1768.